Advaxis Schedules Annual General Meeting

Tuesday, June 1, 2010 | 1000 EDT

NASDAQ OMX 4 Times Square, NYC

NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has scheduled its annual general meeting for Tuesday, June 1, 2010 at 1000 EDT. The meeting will be hosted at Nasdaq OMX headquarters in New York City. Formal invitations will be mailed over the coming few weeks.

“We are very proud to announce the rescheduling our annual general meeting and have it hosted at Nasdaq OMX headquarters”

“We are very proud to announce the rescheduling our annual general meeting and have it hosted at Nasdaq OMX headquarters,” commented Advaxis Chairman/CEO Thomas A. Moore. “We look forward to meeting as many shareholders as we can as we expect to report significant corporate progress on issues to be voted upon that will be important to the future of the Company.”

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.